Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 25, 2021

PARI Pharma receives authorisation for Lamira Nebuliser System in Japan

PARI Pharma has received authorisation for the Lamira Nebulizer System for delivery of Insmed’s drug product, ARIKAYCE (amikacin liposome inhalation suspension), in Japan.

PARI Pharma has received authorisation for the Lamira Nebulizer System for delivery of Insmed’s drug product, ARIKAYCE (amikacin liposome inhalation suspension), in Japan.

The Lamira Nebulizer System has been specially optimised for administering ARIKAYCE.

The drug-specific eFlow Technology nebuliser system comprises a customised medication reservoir that can hold a full 8.4ml dose, a tailored aerosol head for the aerosolisation of ARIKAYCE and the valved aerosol chamber.

PARI Pharma president Dr Martin Knoch said: “Lamira enables us the ability to offer an eFlow Technology nebuliser to patients beyond Europe and North America.

“We are delighted that appropriate patients in Japan suffering from Nontuberculous mycobacterial (NTM) lung disease now have access to a new treatment option.”

Earlier this week, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted approval for ARIKAYCE following approvals in the US and Europe.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

A novel, inhaled, once-daily formulation of amikacin, ARIKAYCE is claimed to be the first inhaled liposomal dispersion approved by the MHLW.

It is also claimed to be the only therapy in Japan for treating patients with NTM lung disease caused by Mycobacterium avium complex (MAC) who have not responded to a previous multidrug regimen treatment.

Insmed Japan general manager Yuji Orihara said: “We are pleased that our valuable partnership with PARI has enabled us to bring to market the first approved drug, ARIKAYCE, to be used with the LAMIRA nebuliser device specifically for the treatment of patients in Japan with refractory MAC lung disease.”

eFlow Technology is an aerosol delivery platform that aids in the effective nebulisation of liquid medications through a vibrating, perforated membrane.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU